CTXR - Citius Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.4452
+0.0252 (+6.00%)
As of 1:00PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.4200
Open0.4300
Bid0.4270 x 3200
Ask0.4453 x 3000
Day's Range0.4000 - 0.4502
52 Week Range0.4000 - 1.7900
Volume109,481
Avg. Volume167,159
Market Cap12.838M
Beta (3Y Monthly)0.04
PE Ratio (TTM)N/A
EPS (TTM)-0.8210
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.65
  • PR Newswire

    Citius Pharmaceuticals to Present at the 12th Annual LD Micro Main Event

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at the 12th Annual LD Micro Main Event on Wednesday December 11, 2019 at 11:40 AM PT. The conference is being held at the Luxe Sunset Boulevard Hotel in Bel Air, California on December 10-12, 2019.

  • PR Newswire

    Citius Pharmaceuticals Issues Corporate Update

    Company provides updates on recent financing and advancements in its product candidates Mino-Lok®, Mino-Wrap™, and Halo-Lido CRANFORD, N.J. , Nov. 8, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:  ...

  • PR Newswire

    Citius Pharmaceuticals to Present at the 5th Annual Dawson James Small Cap Growth Conference

    CRANFORD, N.J. , Oct. 24, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on developing adjunctive ...

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...

  • PR Newswire

    Citius Pharmaceuticals to Present at the MicroCap Rodeo

    CRANFORD, N.J. , Oct. 15, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care ...

  • PR Newswire

    Citius Reaches First Interim Analysis Milestone for Mino-Lok® Pivotal Trial

    CRANFORD, N.J., Oct. 7, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported that the data cutoff for the most recent patient treated and completing 8 weeks of observation has been reached. The Company is preparing the submission to the independent Drug Monitoring Committee ("DMC") for review and evaluation. The objective of the Phase III pivotal trial for Mino-Lok is to evaluate the efficacy and safety of Mino-Lok in salvaging colonized central venous catheters in subjects with catheter-related or central line-associated bloodstream infection (CRBSI/CLABSI) compared to the standard of care using antibiotic locks.

  • PR Newswire

    Citius Provides Update on Activities From IDWeek 2019

    -Management held a Scientific Advisory Board Meeting to present progress on Mino-Lok Phase III trial and its plans for the development of Mino-Wrap -Consensus at Clinical Investigators Meeting: "Mino-Lok ...

  • Insider Buying: The Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Executive Chairman & Secretary Just Bought US$2.0m Worth Of Shares
    Simply Wall St.

    Insider Buying: The Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Executive Chairman & Secretary Just Bought US$2.0m Worth Of Shares

    Those following along with Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) will no doubt be intrigued by the recent...

  • PR Newswire

    Citius Announces Closing of $7.0 Million Underwritten Offering Priced At-the-Market

    CRANFORD, N.J., Sept. 27, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announced underwritten at-the-market offering of 7,821,230 shares of its common stock (Common Stock) (or Common Stock equivalent) and common warrants to purchase up to an aggregate of 7,821,230 shares of Common Stock (the Offering). Each share of Common Stock (or Common Stock equivalent) was sold together with a common warrant to purchase one share of Common Stock at a combined effective price of $0.8951 per share and accompanying common warrant.

  • PR Newswire

    Citius Announces Pricing of $7.0 Million Underwritten Offering Priced At-the-Market

    CRANFORD, N.J., Sept. 25, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the pricing of an underwritten offering of 7,821,230 shares of its common stock (Common Stock) (or Common Stock equivalent) and common warrants to purchase up to an aggregate of 7,821,230 shares of Common Stock (the Offering), priced at-the-market. Each share of Common Stock (or Common Stock equivalent) is being sold together with a common warrant to purchase one share of Common Stock at a combined effective price of $0.8951 per share and accompanying common warrant. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,173,184 shares of Common Stock and/or common warrants to purchase up to 1,173,184 shares of Common Stock.

  • PR Newswire

    Citius Announces Change To Primary Endpoint In Mino-Lok® Phase 3 Study

    CRANFORD, N.J., Sept. 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported that the FDA responded to the Company's proposal to refine the endpoints in the current Phase 3 pivotal trial for Mino-Lok. The current Phase 3 trial being conducted compares Mino-Lok therapy (MLT) to antibiotic lock therapy (ALT) to not only disinfect colonized catheters causing bacteremias, but also to keep the treated catheters functioning and infection free for 8 weeks post therapy.

  • PR Newswire

    Citius Pharmaceuticals, Inc. to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith.

    CRANFORD, N.J. , Aug. 29, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug ...

  • PR Newswire

    Citius Provides Developmental Plans for Mino-Wrap

    CRANFORD, N.J., July 30, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported the Company's decision to develop Mino-Wrap as a drug through the Investigational New Drug ("IND") process. The FDA's IND program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines before a marketing application for the drug has been approved.

  • Have Insiders Been Buying Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Shares?
    Simply Wall St.

    Have Insiders Been Buying Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • Could Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Investor Composition Influence The Stock Price?

    A look at the shareholders of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) can tell us which group is most powerful...

  • PR Newswire

    Citius Pharmaceuticals' Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris

    Candida auris ("C. auris") is a fungus that causes serious infections. C. auris can cause bloodstream infections and even death, particularly in hospital and nursing home patients with serious medical problems.

  • PR Newswire

    Citius Pharmaceuticals to Present at the ThinkEquity Conference

    CRANFORD, N.J. , May 1, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug ...

  • PR Newswire

    Citius Pharmaceuticals Presents Data on Mino-Lok® Showing 98% Clinical Efficacy

    The Data Provides Proof of Salvaging Central Venous Catheters Colonized with Highly Virulent Pathogens in Patients with CLABSI/CRBSI CRANFORD, N.J. , April 30, 2019 /PRNewswire/ -- Citius Pharmaceuticals, ...

  • ACCESSWIRE

    MicroCap Review Magazine Spring 2019 Issue Now Available

    The Digital Issue of the Spring 2019 MicroCap Review Magazine,The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / April 23, 2019 / SNN ...

  • GuruFocus.com

    Citius Pharmaceuticals Inc (CTXR) President and CEO Myron Z Holubiak Bought $200,648 of Shares

    President and CEO of Citius Pharmaceuticals Inc (NASDAQ:CTXR) Myron Z Holubiak bought 129,450 shares of CTXR on 04/03/2019 at an average price of $1.55 a share.

  • PR Newswire

    Citius Pharmaceuticals Successfully Raises $5.3 Million

    Management Again Contributes Significantly CRANFORD, N.J. , April 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company")("CTXR"), a specialty pharmaceutical ...

  • PR Newswire

    Citius Announces $5.3 Million Registered Direct Offering Priced At-the-Market

    CRANFORD, N.J., April 1, 2019 /PRNewswire/ -- Citius Pharmaceuticals Inc. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 3,430,421 shares of its common stock, at a purchase price per share of $1.545 for gross proceeds of approximately $5.3 million, in a registered direct offering priced at-the-market. Additionally, Citius has also agreed to issue to the investors unregistered warrants to purchase up to 3,430,421 shares of common stock. The warrants have an exercise price of $1.42 per share, will be immediately exercisable, and will expire two years from the issue date.

  • ACCESSWIRE

    LD Micro Virtual Conference Is Live, March 12th and 13th

    LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...

  • Imagine Owning Citius Pharmaceuticals (NASDAQ:CTXR) And Taking A 97% Loss Square On The Chin
    Simply Wall St.

    Imagine Owning Citius Pharmaceuticals (NASDAQ:CTXR) And Taking A 97% Loss Square On The Chin

    This month, we saw the Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) up an impressive 45%. But that is meagre solace in the face of the shocking decline over three years. To wit,Read More...